$AGL

Agilon Health (AGL) reported Q2 margin and adjusted EBITDA above guidance midpoints, citing favorable prior-year development, higher risk-adjustment revenue estimates, and medical-cost trend developments. The company ended Q2 with $257M cash and marketable securities and raised 2026 guidance to about $5.8B revenue, $485M medical margin, and $85M adjusted EBITDA. It also cut 2025 medical-cost trend to 5.8% and expects Q3 break-even adjusted EBITDA.

Agilon Health (AGL) shares fell about 19.5% after Q2 results. The company reported Q2 revenue of about $1.49B, with medical margin turning positive to roughly $197M and adjusted EBITDA of about $70M. Net income swung to a profit of about $18M from a prior-year loss, while investors focused on whether margin gains and cost trends are sustainable.

Agilon Health (NYSE:AGL) reported Q2 CY2026 revenue of $1.49 billion, up 7.2% year over year, exceeding Wall Street estimates by 2.8%. Next-quarter revenue guidance was $1.46 billion at the midpoint, about 3.7% above expectations. GAAP EPS was $1.04, well above consensus, and the stock rose 2.6% to $110.51.

agilon health, inc. (AGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agl-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 agilon health Reports Second Quarter 2026 Results Revenue increase 7% to $1.49 billion Raises Full-Year 2026 Total Revenues, Medical Margin, and Adjusted EBITDA Guidance Westerville, O.H., August 5, 2026 – agilon hea

Simply Wall St says AGL Energy has launched promotions including up to A$300 in bill credits for new and moving customers in selected regions, free Netflix Standard with its Netflix Electricity Plan, and added savings when bundling energy with internet or mobile services. The article notes AGL’s FY2026 underlying net profit guidance of A$500 million to A$700 million and discusses potential effects on customer acquisition and retail margins.

agilon health, inc. (AGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex101.htm EX-10.1 Document SEVERANCE AGREEMENT & GENERAL RELEASE This Severance Agreement and General Release (“Agreement”) is between agilon health, inc. (“Company”) and Girish Venkatachaliah (“Employee”). W I T N E S S E T H: WHEREAS, Employee has been employed by the

BRVM indices in West Africa fell after several gain sessions, with the BRVM Composite down 0.27% to 479.92 and BRVM-30 down 0.27% to 228.34, while BRVM Prestige rose 0.21% to 175.23. Ecobank Group-linked ETI TG led declines, down 6.41% to 73 FCFA. Turnover was 2.28 billion FCFA, with ETI TG about 606 million FCFA.

Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.

AGL Energy (ASX:AGL) shares fell 3.67% to close at A$8.13, hitting a new 52-week low after briefly breaking A$8.00. The drop follows FY26 underlying NPAT guidance of A$610m to A$680m and regulatory pressure, including AER-mandated price cuts of up to 10% for 2026-27 default offers.

Australian shares edged up on Monday, led by energy stocks after US strikes against Iran raised oil volatility and uncertainty around the Strait of Hormuz. The ASX 200 rose 0.2% to 8818.80. Woodside and Santos gained; Origin and AGL fell after Macquarie cut AGL. Ampol secured a $400m notes facility; OOh!media’s takeover talks continued with bids up to $1.65/share.